Health topic

Hepatitis C (HCV)

Enabling a targeted response

Hepatitis C—who’s at risk?

 

Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.1

Certain groups are at increased risk of HCV infection. These include people who inject drugs, children born to mothers with HCV and recipients of infected blood products.2

HCV Blood Transmission

From World Health Organization (WHO). https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed January 2023.

Timely diagnosis is the key to effective treatment

 

Hepatitis C is curable in more than 95% of cases. People who test positive for hepatitis C should be treated with direct-acting antiviral (DAA) medication. Timely treatment is important to prevent liver damage and further spread. Treatment saves lives, prevents ongoing spread, and can save costs by stopping the disease from progressing.7

HCV Diagnosis

Proper diagnosis, along with viral load monitoring, allow healthcare professionals to optimally tailor therapy according to virus genotype, viral load (the amount of virus in the blood), and treatment response rate. By combining pharmaceutical and diagnostic innovations, we can deliver tangible benefits to patients more effectively.

 

First in innovation

 

Roche introduced the first-ever test to monitor HCV viral load in 1993 and remains committed to helping eradicate the virus today.

Roche assays support the accurate detection and viral-load quantification of HCV across different genotypes, helping clinicians make decisions that support the best patient care possible.

Related systems

cobas 5800
cobas® 5800 System

Empowering laboratories to balance productivity, efficiency, and potential cost effectiveness with fully automated and standardized workflows, on demand testing and the proven reliability of Roche quality results..

Learn more
RMD_cobas_6800_280x184
cobas® 6800 System

Unparalleled performance, absolute automation, and unmatched flexibility. Meet the needs of molecular testing today and experience the freedom to explore the possibilities for tomorrow.

Learn More
RMD_cobas_8800_280x184
cobas® 8800 System

Unparalleled performance with minimal operator interaction revolutionizes the future of highthroughput applications.

Learn More

References

  1. World Health Organization (WHO). Fact sheet No. 164: Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed January 2023.
  2. Centers for Disease Control and Prevention. Hepatitis C Questions and Answers for Health Professionals. https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#:~:text=The%20following%20people%20are%20at,maintenance%20hemodialysis%20(4%2C5). Accessed January 2023.
  3. U.S. Department of Health & Human Services. Viral Hepatitis in the United States: Data and Trends. https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/data-and-trends/index.html. Accessed January 2023.
  4. Association for Professionals in Infection Control and Epidemiology. Hepatitis C screening for baby boomers. https://apic.org/monthly_alerts/hepatitis-c-screening-for-baby-boomers/. Accessed January 2023.
  5. Mayo Clinic. Liver Transplant. https://www.mayoclinic.org/tests-procedures/liver-transplant/about/pac-20384842. Accessed January 2023
  6. Centers for Disease Control and Prevention. CDC Recommendations for Hepatitis C Screening Among Adults. https://www.cdc.gov/mmwr/volumes/69/rr/rr6902a1.htm. Accessed January 2023.
  7. Centers for Disease Control and Prevention. Too Few People Treated for Hepatitis C. https://www.cdc.gov/vitalsigns/hepc-treatment/index.html. Accessed January 2023.
Found 0 results in
Filters
...
    ...